Viking Therapeutics (NASDAQ:VKTX) Cut to “Buy” at ValuEngine

ValuEngine downgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a strong-buy rating to a buy rating in a report released on Friday, ValuEngine reports.

VKTX has been the topic of a number of other research reports. Oppenheimer started coverage on Viking Therapeutics in a report on Tuesday, July 16th. They issued an outperform rating and a $12.00 price objective on the stock. Citigroup started coverage on Viking Therapeutics in a report on Monday, July 15th. They issued an outperform rating on the stock. CIBC started coverage on Viking Therapeutics in a report on Tuesday, July 16th. They issued an outperform rating and a $12.00 price objective on the stock. HC Wainwright restated a buy rating and issued a $31.00 price objective on shares of Viking Therapeutics in a report on Friday, August 2nd. Finally, Stifel Nicolaus started coverage on Viking Therapeutics in a report on Tuesday, June 25th. They issued a buy rating and a $14.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Viking Therapeutics has a consensus rating of Buy and a consensus price target of $20.53.

NASDAQ:VKTX opened at $6.83 on Friday. The stock’s 50 day moving average price is $7.82 and its 200 day moving average price is $8.33. Viking Therapeutics has a 52 week low of $6.53 and a 52 week high of $24.00. The company has a market capitalization of $472.98 million, a P/E ratio of -17.08 and a beta of 2.29.



Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). On average, equities analysts predict that Viking Therapeutics will post -0.46 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Capital Investment Advisory Services LLC boosted its position in Viking Therapeutics by 126.5% during the second quarter. Capital Investment Advisory Services LLC now owns 3,850 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 2,150 shares during the period. Quantamental Technologies LLC bought a new stake in Viking Therapeutics during the second quarter worth approximately $50,000. Legal & General Group Plc boosted its position in Viking Therapeutics by 38.0% during the fourth quarter. Legal & General Group Plc now owns 10,704 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 2,945 shares during the period. Wedbush Securities Inc. bought a new stake in Viking Therapeutics during the second quarter worth approximately $97,000. Finally, BNP Paribas Arbitrage SA bought a new stake in Viking Therapeutics during the first quarter worth approximately $126,000. 62.91% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Read More: Bear Market – How and Why They Occur

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.